Literature DB >> 19228485

The role of statin therapy in the management of cardiomyopathies.

Kumudha Ramasubbu1, John A Farmer.   

Abstract

The non-lipid-lowering or pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been hypothesized to beneficially alter mechanisms involved in heart failure. Retrospective analyses of heart failure trials as well as small prospective trials with nonmortality clinical and surrogate end points appeared to confirm this presumption. However, two recently published, large, prospective randomized trials did not demonstrate any significant clinical benefit of statins in heart failure patients. This review outlines the proposed biologic effects of statins in heart failure syndrome and clinical evidence of statin use in heart failure patients.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19228485     DOI： 10.1007/s11883-009-0019-5

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


  53 in total

Review 1.  Selenoprotein synthesis and side-effects of statins.

Authors:  Bernd Moosmann; Christian Behl
Journal:  Lancet       Date:  2004-03-13       Impact factor: 79.321

2.  Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy.

Authors:  Jeffrey J Goldberger; Haris Subacius; Andi Schaechter; Adam Howard; Ronald Berger; Alaa Shalaby; Joseph Levine; Alan H Kadish
Journal:  J Am Coll Cardiol       Date:  2006-08-28       Impact factor: 24.094

3.  Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure.

Authors:  Bojan Vrtovec; Renata Okrajsek; Alenka Golicnik; Mateja Ferjan; Vito Starc; Branislav Radovancevic
Journal:  J Card Fail       Date:  2005-12       Impact factor: 5.712

4.  Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy.

Authors:  M Takemoto; K Node; H Nakagami; Y Liao; M Grimm; Y Takemoto; M Kitakaze; J K Liao
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

5.  Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1.

Authors:  P Delerive; K De Bosscher; S Besnard; W Vanden Berghe; J M Peters; F J Gonzalez; J C Fruchart; A Tedgui; G Haegeman; B Staels
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

6.  In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling.

Authors:  Jennifer Martin; Rachel Denver; Michael Bailey; Henry Krum
Journal:  Clin Exp Pharmacol Physiol       Date:  2005-09       Impact factor: 2.557

7.  Impact of HMG CoA reductase inhibition on small GTPases in the heart.

Authors:  Ulrich Laufs; Heiko Kilter; Christian Konkol; Sven Wassmann; Michael Böhm; Georg Nickenig
Journal:  Cardiovasc Res       Date:  2002-03       Impact factor: 10.787

8.  Statin use and survival outcomes in elderly patients with heart failure.

Authors:  Joel G Ray; Yanyan Gong; Kathy Sykora; Jack V Tu
Journal:  Arch Intern Med       Date:  2005-01-10

9.  Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy.

Authors:  Koichi Node; Masashi Fujita; Masafumi Kitakaze; Masatsugu Hori; James K Liao
Journal:  Circulation       Date:  2003-07-28       Impact factor: 29.690

10.  Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism.

Authors:  Masahiro Ito; Takeshi Adachi; David R Pimentel; Yasuo Ido; Wilson S Colucci
Journal:  Circulation       Date:  2004-07-19       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.